771 results on '"Molnár, T."'
Search Results
2. The Effects of Delay on the HKB Model of Human Motor Coordination
3. P1016 Real-world data on sequential therapy in moderate-to-severe UC: Unveiling second-line strategies after anti-TNF failure
4. P356 Long-term outcome of UC patients in clinical remission with different level of mucosal activity: real world, retrospective, multicontinental study
5. P845 Vedolizumab induces endoscopic healing uniformly irrespective of disease location: post-hoc analysis of the LOVE-CD trial
6. P674 Real-world experiences of switching to subcutaneous formulation in IBD patients on maintenance vedolizumab treatment
7. P938 Effectiveness and safety of switching from original infliximab to GP1111 biosimilar in inflammatory bowel diseases – prospective, cohort study
8. P560 The impact of reactive point-of-care drug level measurement on the medium-term course of inflammatory bowel disease
9. Coding-complete sequence of a vaccine-derived recombinant porcine reproductive and respiratory syndrome virus strain isolated in Hungary
10. Role of microparticles derived from monocytes, endothelial cells and platelets in the exacerbation of COPD
11. On the analysis of the double Hopf bifurcation in machining processes via centre manifold reduction
12. l-Arginine Pathway Metabolites Predict Need for Intra-operative Shunt During Carotid Endarterectomy
13. ECCO Guidelines on Inflammatory Bowel Disease and Malignancies.
14. N23 Burnout among European IBD specialists – a survey supported by ECCO
15. P576 Endoscopic healing with vedolizumab in Crohn's disease occurs predominantly in the first 6 months and is independent of serum concentrations: Data from LOVE-CD
16. P309 Accuracy of PanMayo endoscopic score in predicting long-term disease outcomes in ulcerative colitis– a promising scoring system
17. P605 Real life efficacy of tofacitinib in different situation in ulcerative colitis: a retrospective worldwide multicentre collaborative study
18. P739 Sequential treatment is effective to achieve remission and avoid colectomy in moderate-to-severe Ulcerative Colitis refractory to anti-TNF therapy
19. DOP13 Plasma metabolite fingerprint could discriminate inflammatory bowel disease patients from healthy subjects
20. P797 Self-reported efficacy and safety of infliximab and adalimumab biosimilars after non-medical switch in patients with Inflammatory Bowel Disease: Results of a multicenter survey
21. P733 Novelties of COVID-19 vaccination beyond efficacy: Nationwide experiences with trough levels, durability, and disease activity among inflammatory bowel disease patients
22. LINEE GUIDA EUROEE
23. DOP007 Efficacy of vedolizumab induction therapy on clinical and endoscopic activity in patients with anti-tumour necrosis factor alpha-resistant inflammatory bowel disease
24. P065 Determination of the cytokine pattern of human colon organoids derived from Inflammatory Bowel Disease patients
25. Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies.
26. P675 Infliximab biosimilar CT-P13 therapy is effective in maintaining clinical remission in Crohnʼs disease and ulcerative colitis – 54 week data
27. P317 Postoperative complications, outcome, quality of life and self-image after ileal pouch-anal anastomosis in patients operated due to acute, severe or chronic, therapy refractory ulcerative colitis
28. P279 Children born to mothers with inflammatory bowel disease – Is there any risk for newbornsʼ complication and development during the childhood?
29. Bile acids inhibit Na+/H+ exchanger and Cl−/HCO3 − exchanger activities via cellular energy breakdown and Ca2+ overload in human colonic crypts
30. Surgery Due to Inflammatory Bowel Disease During Pregnancy: Mothers and Offspring Outcomes From an Ecco Confer Multicentre Case Series (Scar Study)
31. The factor structure of the Opening Minds Stigma Scale for Healthcare Providers on psychiatrists from 32 European countries
32. Evaluation of Metastatic Lymph Nodes by Means of FDG PET
33. Quantification of FDG Uptake Using Kinetic Models
34. P713 Gut microbiota alterations after bowel preparation amongst inflammatory bowel disease patients
35. P352 Ustekinumab is associated with superior treatment persistence compared to vedolizumab in Crohn’s disease patients who failed to anti-TNF therapy: results from a Hungarian cohort study
36. P463 Serum and mucosal Serpin E1 concentration correlates with endoscopic activity in inflammatory bowel disease - potential new activity marker
37. P279 Prevalence of iron deficiency in inflammatory bowel disease
38. P721 Faecal microbiota analysis with body composition and nutritional habits simultaneously amongst Crohn’s disease patients
39. P444 COVID-19 risk factors, infection course and vaccination among patients with inflammatory bowel disease based on a Hungarian cohort
40. P572 Therapy optimisation and intravenous ferric carboxymaltose in active or inactive IBD with iron deficiency: it’s time to make iron deficiency part of tight monitoring to reach T2T? – preliminary results of a prospective study
41. P046 Disease modelling of Inflammatory Bowel Disease by human colon organoids
42. Clinical trial: Preliminary efficacy and safety study of a new Budesonide-MMX ® 9 mg extended-release tablets in patients with active left-sided ulcerative colitis
43. Erratum to: P459 Expression of SerpinE1, a potential new disease activity marker, reflects therapeutic response in Inflammatory Bowel Disease
44. In Vivo Tracking of Maturation in Male European Eel, Anguilla Anguilla (L.), by Computed Tomography
45. Is the efficacy of successful infliximab induction therapy maintained for one year lasting without retreatment in different behavior types of Crohn's disease?
46. ATG16L1 and IL23 receptor (IL23R) genes are associated with disease susceptibility in Hungarian CD patients
47. Letter: role of diet in the onset and relapse of inflammatory bowel disease from the patients’ perspective
48. The relationship between mental-health-related stigma among psychiatrists and country indicators across Europe.
49. P459 Expression of SerpinE1, a potential new disease activity marker, reflects therapeutic response in Inflammatory Bowel Disease
50. P546 The safety and efficacy of the new-generation budesonide-MMX in the aspect of the cytochrome P-450 enzyme genotype
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.